Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482928 | 0.85 | SLC6A2 (0.55) | MAPTMAPK1ANO1FDPSGRM2 | |
| SCHEMBL15546805 | 0.85 | ANO1 (0.41) | MAPTMAPK1ANO1FDPSGRM2 | |
| SCHEMBL2600030 | 0.84 | CNR2 (0.43) | ESR1MAPTFDPSSLC6A3SLC6A4 | |
| SCHEMBL13144963 | 0.83 | ANO1 (0.36) | MAPTMAPK1ANO1FDPSGRM2 | |
| SCHEMBL13509548 | 0.83 | PNMT (0.36) | MAPTMAPK1ANO1FDPSGRM2 | |
| SCHEMBL15583897 | 0.82 | CYP2D6 (0.47) | MAPTMAPK1ANO1GRM2SLC6A3 | |
| SCHEMBL16589323 | 0.82 | ANO1 (0.38) | MAPTMAPK1ANO1FDPSGRM2 | |
| SCHEMBL74006 | 0.81 | IDO1 (0.52) | ESR1MAPTFDPSSLC6A3SLC6A4 | |
| SCHEMBL73649 | 0.81 | ESR1 (0.46) | ESR1SLC6A3SLC6A4SLC6A2HTR2A | |
| SCHEMBL15583953 | 0.81 | PNMT (0.41) | MAPTMAPK1ANO1GRM2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | GLYCOMIMETICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11845764-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-12-19 | — | — | US | disclosed |
| US-11684609-B2 | Compounds and methods for treating an epileptic disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-06-15 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2022-10-18 | — | — | US | disclosed |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-01 | — | — | US | disclosed |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-06-14 | — | — | US | disclosed |
| US-20110052536-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-20110052536-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-03 | — | — | US | disclosed |
| US-20100260717-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-10-14 | — | — | US | disclosed |
| US-7741345-B2 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741345-B2 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2010-02-04 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| US-20090099096-A1 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | ESR1 943/4885MAPT 2371/4885MAPK1 3406/4885 |
| US-20110052536-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, RNGTT | ESR1 4382/4885MAPT 4352/4885MAPK1 4652/4885 |
| US-20120148534-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | EIF2AK2, NSUN3, NSUN2 | ESR1 4307/4885MAPT 4569/4885MAPK1 4363/4885 |
| US-20100260717-A1 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | HAVCR2, MAVS, EIF2AK2 | ESR1 4001/4885MAPT 2810/4885MAPK1 4685/4885 |
| US-20230181592-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | ADORA1, OXGR1, ADORA2A | ESR1 2383/4885MAPT 4295/4885MAPK1 1840/4885 |
| US-11472807-B2 | Purine derivatives for use as medicament and for use in treating neurodegenerative or neuro-inflammatory disorders | TPMT, ADORA2A, PNP | ESR1 4597/4885MAPT 90/4885MAPK1 1517/4885 |
| US-11845764-B2 | Organic electroluminescent materials and devices | LIFR, L1CAM, LBR | ESR1 135/4885MAPT 4367/4885MAPK1 1538/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | ESR1 4439/4885MAPT 89/4885MAPK1 1113/4885 |
| US-11873317-B2 | Galectin-3 inhibiting c-glycosides | LGALS3, LGALS3BP, LGALS1 | ESR1 4482/4885MAPT 2827/4885MAPK1 898/4885 |
| US-20090099096-A1 | AZA-peptide protease inhibitors | DNPEP, ANPEP, PEPD | ESR1 3026/4885MAPT 2252/4885MAPK1 1537/4885 |
| US-11684609-B2 | Compounds and methods for treating an epileptic disorder | GABRE, SLC6A1, GABBR1 | ESR1 2922/4885MAPT 498/4885MAPK1 4452/4885 |
| US-20120276050-A1 | METHODS AND COMPOSITIONS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION | NSUN3, RNGTT, NSUN2 | ESR1 4687/4885MAPT 4638/4885MAPK1 4422/4885 |
| US-20100028299-A1 | Methods and compositions of treating a flaviviridae family viral infection | EIF2AK2, NSUN3, NSUN2 | ESR1 4307/4885MAPT 4569/4885MAPK1 4363/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | ESR1 4540/4885MAPT 3549/4885MAPK1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.